Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2–negative early breast cancer: a multi-center retrospective study

被引：0
|
作者：
Weibin Lian [1 ]
Liangqiang Li [1 ]
Debo Chen [1 ]
Chengye Hong [1 ]
机构：
[1] Affiliated Quanzhou First Hospital of Fujian Medical University,Department of Breast Surgery
来源：
BMC Cancer | / 25卷 / 1期
关键词：
Breast cancer; Ovarian function suppression; Composite recurrence risk score; Disease-free survival;
D O I：
10.1186/s12885-025-14120-0
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer
    Basmadjian, Robert B.
    Lupichuk, Sasha
    Xu, Yuan
    Quan, May Lynn
    Cheung, Winson Y.
    Brenner, Darren R.
    JAMA NETWORK OPEN, 2024, 7 (03) : E242082
  • [2] Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study
    Ozaki, Y.
    Tamura, N.
    Utiyama, M.
    Masuda, J.
    Koganemaru, S.
    Miura, Y.
    Tanabe, Y.
    Ogura, T.
    Kadowaki, M.
    Miura, D.
    Kawabata, H.
    Takano, T.
    CANCER RESEARCH, 2016, 76
  • [3] Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
    Regan, Meredith M.
    Francis, Prudence A.
    Pagani, Olivia
    Fleming, Gini F.
    Walley, Barbara A.
    Viale, Giuseppe
    Colleoni, Marco
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo
    Pinotti, Graziella
    Price, Karen N.
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2221 - +
  • [4] Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer
    Lambertini, Matteo
    Viglietti, Giulia
    de Azambuja, Evandro
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 43 - 51
  • [5] Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer
    Gogineni, Keerthi
    Kalinsky, Kevin
    JCO ONCOLOGY PRACTICE, 2022, 18 (04) : 247 - +
  • [6] Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer
    Bui, Kim Tam
    Willson, Melina L.
    Goel, Shom
    Beith, Jane
    Goodwin, Annabel
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (03):
  • [7] The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer
    Jain, Sarika
    Santa-Maria, Cesar Augusto
    Gradishar, William J.
    ONCOLOGY-NEW YORK, 2015, 29 (07): : 473 - +
  • [8] Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Khanzada, Mikail
    Zaheer, Zaofashan
    Fatima, Eeshal
    Bakhtiar, Muhammad
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [9] Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
    Lu, Yen-Shen
    Wong, Andrea
    Kim, Hee-Jeong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer A network meta-analysis
    Jiang, Mengjie
    Chen, Wuzhen
    Hu, Yujie
    Chen, Chao
    Li, Huafeng
    MEDICINE, 2021, 100 (33)
12345